drugset / Trial / NCT06414733
HER-2 B Cell Peptide Vaccine
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This phase I trial studies the side effects and best dose of vaccine therapy in treating patients with metastatic solid tumors. Vaccines made from antibodies and peptides combined with tumor cells may help the body build an effective immune response to kill tumor cells.
Timeline
- Start
- 2025-01-17
- Primary completion
- 2029-12-31
- Completion
- 2030-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MVF HER2 597-626 | Peptide | 1.5 mg | Intramuscular |
| Subject | MVF-HER2 266-296 | Peptide | 1.5 mg | Intramuscular |